A Phase 3 interventional study of secukinumab 150 mg in Moderate to Severe Chronic Plaque-type Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 67 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-11.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.
Among the 54 studies testing secukinumab in Psoriasis, this one is the 10th largest by enrollment, is one of 2 that started in 2018, is one of 24 in phase 3, and was the 40th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
University of Athens · Sites in Greece
Ages 18–80 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Singapore General Hospital · Sites in Singapore
Ages 22–90
By country, each count listing its studies:
secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 24 · Phase 4 17
First in 2007; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 331 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 124 across the 54 interventional studies. Of the 46 that completed or were terminated, 38 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 54 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
68 studies in Psoriasis by Novartis: 3 open now, 4 under way, none of them phase 3. Of 61 finished, 41 (67%) have results posted.
Among the 68 studies in Psoriasis by Novartis, this one is the 16th largest by enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2018, is one of 30 in phase 3, and was the 49th registered.
Novartis’s Psoriasis studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing secukinumab in Psoriasis, from their registry updates:
Among Novartis’s 68 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess secukinumab high dose (every 2 weeks) vs standard dose (every 4 weeks) in heavy body weight subjects with moderate to severe plaque psoriasis.
A 52-week multicenter, randomized, double-blind, parallel-group trial in 331 subjects with moderate to severe chronic plaque-type psoriasis of body weight 90 kg or higher at time of randomization.
This study consisted of 4 periods: screening (up to 4 weeks), treatment Period 1 (16 weeks), treatment Period 2 (36 weeks), and post-treatment follow-up (8 weeks).
Subjects were randomized using a 1:1 ratio to the following groups: Secukinumab 300 mg every 2 weeks; Secukinumab 300 mg every 4 weeks.
In addition, subjects from the 300 mg every 4 weeks group who did not achieve Psoriasis Area Severity Index (PASI) 90 response at Week 16 were reassigned using a 1:1 ratio to either remain on secukinumab 300 mg every 4 weeks or receive secukinumab 300 mg every 2 weeks starting at Week 16, until the end of treatment.
Key Inclusion Criteria:
Moderate to severe psoriasis as defined at randomization by:
Candidate for systemic therapy. This is defined as a subject having moderate to severe chronic plaque-type psoriasis that is inadequately controlled by:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 injections of secukinumab 150 mg once weekly up to week 4 and thereafter every 2 weeks. Subjects remained on secukinumab 300 mg every 2 weeks until the end of treatment.
Drug: secukinumab 150 mg
2 injections of secukinumab 150 mg once weekly up to week 4 and thereafter Q4W. Includes both subjects randomized to remain on Q4W the entire treatment period, and subjects that were Psoriasis Area and Severity Index (PASI) 90 responders at Week 16 from the secukinumab 300 mg Q4W possible up-titrate group.
Drug: secukinumab 150 mg
2 injections of secukinumab 150 mg once weekly up to week 4, then Q4W up to Week 16 and thereafter Q2W. Includes Psoriasis Area and Severity Index (PASI) 90 non-responders (NR) at Week 16 from the secukinumab 300 mg Q4W possible up-titrate group (subjects randomized to switch to Q2W if PASI 90 non-responder at Week 16).
Drug: secukinumab 150 mg
sub-cutaneous secukinumab prefilled syringe 150 mg
Percentage of Subjects Who Achieve 90% or Greater Reduction in Psoriasis Area and Severity Index (PASI) Score - Week 16 (Full Analysis Set)
A subject was considered as a PASI 90 responder if s/he achieved a reduction of 90% or more of the PASI score, compared to baseline, at a given time point.The head, trunk, upper limbs and lower limbs were assessed separately for erythema, thickening, and scaling. PASI scores can range from a lower value of 0, corresponding to no signs of psoriasis, up to a theoretic maximum of 72.0, i.e., higher scores represent more severity.
Time frame: 16 weeks
Percentage of Subjects Who Achieve Investigator Global Assessment (IGA Modified 2011) Score of 0 or 1 - Week 16 (Full Analysis Set)
IGA mod 2011 was conducted for overall psoriatic disease. The IGA modified 2011 used in this study was static, i.e., it referred exclusively to the subject's disease state at the time of the assessments, and did not attempt a comparison with any of the subject's previous disease states, whether at baseline or at a previous visit. The scale has 0 (clear) as min and 4 (severe) as max, i.e., a higher score indicates more severity.
Time frame: 16 weeks
Absolute and Relative Frequencies for Deaths, Other Serious or Clinically Significant Adverse Events or Related Discontinuations - Entire Study Period (Safety Set)
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject after providing written informed consent for participation in the study until the end of study visit. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.
Time frame: Adverse events were reported from first dose of study treatment until end of study treatment plus 8 weeks post treatment, up to a maximum timeframe of 470 days.
| Milestone | Secukinumab 300 mg Every 2 Weeks (Q2W) | Secukinumab 300 mg Every 4 Weeks (Q4W) (Safety) | Secukinumab 300 mg Every 4 Weeks Non-responders Up-titration (Q4W NR up) |
|---|---|---|---|
| Started | 165 | 135 | 31 |
| Completed | 148 | 117 | 28 |
| Not completed | 17 | 18 | 3 |
| Withdrew: Withdrawal of informed consent | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 5 | 5 | 1 |
| Withdrew: Lost to follow-up | 4 | 1 | 0 |
| Withdrew: New therapy for study indication | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 2 | 0 |
| Withdrew: Death | 0 | 1 | 0 |
| Withdrew: Adverse event | 4 | 8 | 2 |
A subject was considered as a PASI 90 responder if s/he achieved a reduction of 90% or more of the PASI score, compared to baseline, at a given time point.The head, trunk, upper limbs and lower limbs were assessed separately for erythema, thickening, and scaling. PASI scores can range from a lower value of 0, corresponding to no signs of psoriasis, up to a theoretic maximum of 72.0, i.e., higher scores represent more severity.
| Participants | Secukinumab 300 mg Every 2 Weeks (Q2W) | Secukinumab 300 mg Every 4 Weeks (Q4W) (up to Week 16 Pre-dose) |
|---|---|---|
| Percentage of Subjects Who Achieve 90% or Greater Reduction in Psoriasis Area and Severity Index (PASI) Score - Week 16 (Full Analysis Set) | 121 | 92 |
IGA mod 2011 was conducted for overall psoriatic disease. The IGA modified 2011 used in this study was static, i.e., it referred exclusively to the subject's disease state at the time of the assessments, and did not attempt a comparison with any of the subject's previous disease states, whether at baseline or at a previous visit. The scale has 0 (clear) as min and 4 (severe) as max, i.e., a higher score indicates more severity.
| Participants | Secukinumab 300 mg Every 2 Weeks (Q2W) | Secukinumab 300 mg Every 4 Weeks (Q4W) (up to Week 16 Pre-dose) |
|---|---|---|
| Percentage of Subjects Who Achieve Investigator Global Assessment (IGA Modified 2011) Score of 0 or 1 - Week 16 (Full Analysis Set) | 122 | 109 |
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject after providing written informed consent for participation in the study until the end of study visit. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.
| Participants | Secukinumab 300 mg Every 2 Weeks (Q2W) | Secukinumab 300 mg Every 4 Weeks (Q4W) (Safety) | Secukinumab 300 mg Every 4 Weeks Non-responders Up-titration (Q4W NR up) |
|---|---|---|---|
| Patients with any AE(s) | 127 | 97 | 24 |
| Patients with serious or other significant events - Death | 0 | 1 | 0 |
| Patients with serious or other significant events - Non-fatal SAE(s) | 14 | 17 | 4 |
| Patients with serious or other significant events - Discontinued study treatment due to any AE(s) | 4 | 9 | 2 |
Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 8 weeks post treatment, up to a maximum timeframe of 470 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Secukinumab 300 mg Every 2 Weeks (Q2W) | 0/165 (0%) | 14/165 (8.5%) | 66/165 (40%) |
| Secukinumab 300 mg Every 4 Weeks (Q4W) (Safety) | 1/134 (0.7%) | 18/134 (13.4%) | 57/134 (42.5%) |
| Secukinumab 300 mg Every 4 Weeks Non-responders Up-titration (Q4W NR up) | 0/31 (0%) | 4/31 (12.9%) | 16/31 (51.6%) |
| All Patients | 1/330 (0.3%) | 36/330 (10.9%) | 139/330 (42.1%) |
| Event | Secukinumab 300 mg Every 2 Weeks (Q2W) | Secukinumab 300 mg Every 4 Weeks (Q4W) (Safety) | Secukinumab 300 mg Every 4 Weeks Non-responders Up-titration (Q4W NR up) | All Patients |
|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/165 | 1/134 | 1/31 | 2/330 |
| TachycardiaCardiac disorders | 0/165 | 1/134 | 1/31 | 2/330 |
| Inguinal herniaGastrointestinal disorders | 0/165 | 0/134 | 1/31 | 1/330 |
| Cholecystitis chronicHepatobiliary disorders | 0/165 | 0/134 | 1/31 | 1/330 |
| PneumoniaInfections and infestations | 0/165 | 0/134 | 1/31 | 1/330 |
| Tooth abscessInfections and infestations | 0/165 | 0/134 | 1/31 | 1/330 |
| FallInjury, poisoning and procedural complications | 1/165 | 0/134 | 1/31 | 2/330 |
| SepsisInfections and infestations | 0/165 | 2/134 | 0/31 | 2/330 |
| Non-cardiac chest painGeneral disorders | 2/165 | 0/134 | 0/31 | 2/330 |
| Acute myocardial infarctionCardiac disorders | 0/165 | 1/134 | 0/31 | 1/330 |
| Event | Secukinumab 300 mg Every 2 Weeks (Q2W) | Secukinumab 300 mg Every 4 Weeks (Q4W) (Safety) | Secukinumab 300 mg Every 4 Weeks Non-responders Up-titration (Q4W NR up) | All Patients |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 32/165 | 22/134 | 5/31 | 59/330 |
| Upper respiratory tract infectionInfections and infestations | 12/165 | 9/134 | 3/31 | 24/330 |
| Neutrophil count decreasedInvestigations | 1/165 | 3/134 | 3/31 | 7/330 |
| IntertrigoSkin and subcutaneous tissue disorders | 4/165 | 0/134 | 3/31 | 7/330 |
| HeadacheNervous system disorders | 11/165 | 6/134 | 1/31 | 18/330 |
| DiarrhoeaGastrointestinal disorders | 10/165 | 6/134 | 2/31 | 18/330 |
| NauseaGastrointestinal disorders | 1/165 | 4/134 | 2/31 | 7/330 |
| FatigueGeneral disorders | 4/165 | 3/134 | 2/31 | 9/330 |
| PyrexiaGeneral disorders | 2/165 | 2/134 | 2/31 | 6/330 |
| Tooth abscessInfections and infestations | 1/165 | 0/134 | 2/31 | 3/330 |
| Age, Continuous(years) | Secukinumab 300 mg Every 2 Weeks (Q2W) | Secukinumab 300 mg Every 4 Weeks (Q4W) (Safety) | Secukinumab 300 mg Every 4 Weeks Non-responders Up-titration (Q4W NR up) | Total |
|---|---|---|---|---|
| Mean | 48.2 ± 12.73 | 46.1 ± 13.24 | 44.7 ± 13.61 | 47.1 ± 13.04 |
| Sex: Female, Male(Participants) | Secukinumab 300 mg Every 2 Weeks (Q2W) | Secukinumab 300 mg Every 4 Weeks (Q4W) (Safety) | Secukinumab 300 mg Every 4 Weeks Non-responders Up-titration (Q4W NR up) | Total |
|---|---|---|---|---|
| Female | 39 | 34 | 10 | 83 |
| Male | 126 | 101 | 21 | 248 |
| Race (NIH/OMB)(Participants) | Secukinumab 300 mg Every 2 Weeks (Q2W) | Secukinumab 300 mg Every 4 Weeks (Q4W) (Safety) | Secukinumab 300 mg Every 4 Weeks Non-responders Up-titration (Q4W NR up) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 0 | 2 |
| Asian | 4 | 4 | 1 | 9 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 0 | 2 |
| Black or African American | 7 | 5 | 0 | 12 |
| White | 151 | 125 | 30 | 306 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Jun 2018 to primary completion in Sep 2019, 14 months.
Results were first posted in Jun 2021, 1 year 8 months after primary completion. A results delay was requested in Jul 2020.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 14 months is close to that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab